$EHOS DD
IT IS MY OPINION, That one should expect an
$EHOS DD
IT IS MY OPINION, That one should expect an increase in interest here as key material events have occurred since Oct 2nd- that generally lead OTC investors to believe that we are at the precipice of something major revealing itself.
Frankly, what's even more compelling: the owners of this shell did NOT press release or PUMP these changes to sell any shares. They have no interest in selling shares. This is not current and they can't dilute! .
WHAT WE KNOW:
1- A/S- 5 Bil O/S : likely around 1.5 bil
2- THEY CANT DILUTE
3- On Oct 2nd- the website www.ehouse-global.com was renewed /re-created according to the website www.whois.com - whixh is very intriguing since it wasn't ever up for renewal. A careful look show though shows it was actually recreated on Oct2nd 2017. That leads me to believe that new management is working on a new website
4- OTC Markets updated their OFFICERS listed for EHOS on 10/12 -- to reflect a new CEO Michael Bagley and Treasurer/Secretary as Paul L Strickland. THIS IS A MAJOR CONFIRMATION FOR the near future of $EHOS. They also left 4 guys listed as Directors- including Scott Johnson, BW Geer, Brandon Halbrook with Paul L. Strickland.
5- More DD into Paul L Strickland yields incredible connections to Washington Agrculture and Commerce and he also serves as Governor of a public entity that operates as an EB-5 regional center for investments.
He is directly tied to two companies now over the last 3 weeks that are in the MJ business - which is quite intriguing.
6- ONLY 300mil or $60k is on The ask at .0002 pps. That's nothing. Easily can go in a few hours of heavy buying. This one moved so quick on the pretense earlier this year that something might happen here. Now I'm quite certain something will- and it will be MJ. The recent updates are very telling and the best indicator we are extremely close to uncovering a potentially new major MJ stock for the OTC, Looking forward to revealing more on CEO Bagley and Treasurer/Sec Strickland this week.
Paul L. Strickland has major connections already displayed and through his capital company with guys like Paul Kirkland. AMVISA Capital
In my opinion, this under the radar GEM is about to be uncovered and those who found their way here already stand to gain for their decision to use foresight and understand risk vs reward. This is trading at the very bottom and one can only presume that as legal MJ in Cali and Washington gains steam -it's no wonder this is now unde got acrual material events that are worthy of the aforementioned notice.
dd dempsey
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Data Breach Fallout: Amplifon Under Fire When a big player like Amplifon gets hit with a data breach, it's like a wake-up call across the board. This one’s no small spill—over 1.3 million folks left wondering whether their personal information is fluttering around cyberspace for all who dare to peek. If you’ve missed the memo, Edelson Lechtzin LLP, the savvy cats in...
Continue Reading
Antengene's AnTenGager-D2 Offers Fresh Hope Alright, let's dig into the latest buzz from the 2026 Society for Immunotherapy of Cancer conference about Antengene's AnTenGager-D2 platform. If you're not into biotech lingo, buckle up, because this is a ride into the future of cancer treatments—where science fiction might soon become science fact. A Novel Approach to Tumor...
Continue Reading
Enhanced Patient Satisfaction with Aesthetic Treatments Dive into the latest studies from Allergan Aesthetics—AbbVie's heavyweight in the beauty battleground. If you've got an ounce of optimism left in this market, their recent findings might just lift your spirits. Phase 4 studies, namely HARMONY IN DIVERSITY and HALO, are showing highly positive results among patients...
Continue Reading
The Clock is Ticking for Webull Investors If anyone's got a Webull stake, listen up! You’ve got a deadline that's staring you in the face: December 7, 2026. This is when you need to throw your hat in the ring to be a lead plaintiff in the Webull Corporation class action. We're talking securities fraud, folks, with allegations flying that would make your head spin....
Continue Reading
Imagine a world where simply sleeping in cleaner air could affect your blood sugar. Seems far-fetched, I know. But that's where we're at with this new study out of NYU Langone Health. They're talking about using plain ol' portable air filters to help steady blood sugar levels for folks dealing with prediabetes. Turns out a cleaner bedroom might just hold the key to taming...
Continue Reading
Why LG's ASIL D Certification Matters There ain't much in the tangled mess of automotive innovations these days that'll make a seasoned investor raise an eyebrow, but here comes LG Electronics grabbing the ASIL D certification like it's a badge of market honor. The ISO 26262 ASIL D is no walk in the park, folks—it's the top rung on the safety ladder, something that's...
Continue Reading
A Strategic Step into the Japanese Market Alright folks, there's a new kid aiming to shake things up in the biotech neighborhood, and it's GlycoNex with its denosumab biosimilar, SPD8. These guys just tossed their hat in the ring with a regulatory submission to Japan's Pharmaceuticals and Medical Devices Agency (PMDA). If the cosmic forces align, they might snag an...
Continue Reading
Gildan Investors, Brace Yourself Poor old Gildan Activewear finds itself in hot water again, with a class action lawsuit cropping up like an unexpected storm on farmers' day. Any traders remotely involved with NYSE:GIL should pay damn close attention, because with a December 14, 2026 deadline looming, it's crunch time. The Root of the Lawsuit The plot thickens here,...
Continue Reading
The AI Race Heats Up with FFR's Big Win Stop the presses—FFR's OmniMind AI just snagged the top spot on RoboColiseum's global rankings. Yeah, you heard right, this ain't just some run-of-the-mill news. As of November 6, they've parked themselves in pole position, beating out heavyweights like NVIDIA's GR00T N1.7 and GPT-6 Astra. That's like hitting a grand slam right...
Continue Reading
China's Grand Vision for Intelligent Communication You know what they say about big ideas—they start in the most bustling of places. And here we are in Wuxi, a city's pulse pounding with ambition, hosting the 2026 China International Intelligent Communication Forum. Picture it: From November 8th to 10th, movers, shakers, and visionaries are scribbling new blueprints for...
Continue Reading
Top 5 Most Recently Viewed Articles
AI's Rising Star in Enterprise Marketing Here's a tidbit worth chewing over your morning coffee: SOCi Inc., a name that's been buzzing in the enterprise circles, has nailed top spots in G2's Summer 2026 Report. We're talking about leading the charge in AI marketing and localized visibility, territories tough to crack unless you've got serious chops. In a world where...
Continue Reading
AI and the Future of Staffing: A Growth Story The staffing services market is on the verge of a major transformation, thanks in large part to advancements in Artificial Intelligence (AI). This evolution is projected to add an astounding USD 236.6 billion to the global staffing services market between 2024 and 2028. During this time, the market is expected to experience a...
Continue Reading
Strategic Collaboration Between OCC and Lightera Optical Cable Corporation (NASDAQ: OCC) and Lightera, LLC are entering a significant partnership aimed at enhancing their product offerings primarily in the data center and enterprise sectors. This collaboration builds upon their long-term relationship, combining their strengths to create innovative optical connectivity...
Continue Reading
INFINOX Appoints Artem Gonov as Chief Technology Officer INFINOX, a globally recognized brokerage, has recently appointed Artem Gonov as its new Chief Technology Officer (CTO). This strategic move underlines the company's commitment to enhancing its technology landscape and providing exceptional platforms for its clients. Artem Gonov's Background and Expertise Mr. Gonov...
Continue Reading
George Medicines Introduces GMRx2 for Hypertension Management Recent findings published in The Lancet highlighted the promising results of a Phase III trial for GMRx2, a novel triple combination pill aimed at managing hypertension. Developed by George Medicines, this medication is making waves in the field of cardiovascular care as it demonstrates significant advancements...
Continue Reading